Pieris Pharmaceuticals
Pieris Pharmaceuticals, based in Boston, MA, USA and Hallbergmoos, Germany, specializes in immuno-oncology, developing 4-1BB bispecific programs in collaboration with Pfizer, Servier, and Boston Pharmaceuticals.
Company Overview
Pieris Pharmaceuticals is a biotechnology company with a focus on immuno-oncology. It has offices in Boston, MA, USA, and Hallbergmoos, Germany. The company develops innovative therapies aimed at treating cancer by engaging the immune system.
Partnerships with Pfizer, Servier, and Boston Pharmaceuticals
Pieris Pharmaceuticals has developed 4-1BB bispecific programs in collaboration with Pfizer, Servier, and Boston Pharmaceuticals. These pharmaceutical partners fund 100% of the costs associated with these programs, allowing Pieris to focus on research and development.
4-1BB Bispecific Programs
Pieris Pharmaceuticals is working on 4-1BB bispecific programs as part of its immuno-oncology initiatives. These programs are in various stages of clinical development, aiming to create effective cancer treatments. Shareholders can gain from future milestones and royalties resulting from these programs.
Financial Milestones and Royalties
Pieris Pharmaceuticals is eligible for development, regulatory, and sales-based milestones, as well as sales royalties from its 4-1BB bispecific immuno-oncology assets. This financial structure provides an opportunity for the company to benefit from its partnered clinical developments.
Global Presence
The company operates from two strategic locations: Boston, MA, USA, and Hallbergmoos, Germany. Both offices play a crucial role in supporting Pieris Pharmaceuticals’ global operations and R&D activities in the field of immuno-oncology.